GLUE vs. NUTX

Last updated Jun 3, 2026

GLUE (Monte Rosa Therapeutics, Inc.) and NUTX (Nutex Health Inc) are both stocks. Both are in the Healthcare sector — GLUE in Biotechnology, NUTX in Health Information Services. Over the past 3 years, GLUE returned 32.89%/yr vs 22.61%/yr for NUTX. At a 0.14 correlation, their price movements are largely independent.

Performance

GLUE vs. NUTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Monte Rosa Therapeutics, Inc. (GLUE) and Nutex Health Inc (NUTX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GLUE achieves a 13.14% return, which is significantly higher than NUTX's -24.05% return.

GLUE

• 1D: -9.81%
• 1M: -5.64%
• YTD: 13.14%
• 6M: 15.12%
• 1Y: 294.22%
• 3Y*: 32.89%
• 5Y*: —
• 10Y*: —

NUTX

• 1D: -2.34%
• 1M: -10.42%
• YTD: -24.05%
• 6M: -3.65%
• 1Y: -25.56%
• 3Y*: 22.61%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

GLUE vs. NUTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
GLUE Monte Rosa Therapeutics, Inc.	13.14%	125.94%	22.83%	-25.76%	-49.23%
NUTX Nutex Health Inc	-24.05%	419.47%	17.37%	-90.53%	-95.25%

Correlation

The correlation between GLUE and NUTX is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (All Time) Calculated using the full available price history since Apr 5, 2022	0.14

Fundamentals

EPS GLUE : -$2.26 NUTX : $19.08
PS Ratio GLUE : 23.76 NUTX : 0.72
Total Revenue (TTM) GLUE : $42.95M NUTX : $879.95M
Gross Profit (TTM) GLUE : $34.56M NUTX : $417.67M
EBITDA (TTM) GLUE : -$139.25M NUTX : $275.94M

Return for Risk

GLUE vs. NUTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GLUE

GLUE Risk / Return Rank: 94
GLUE Sharpe Ratio Rank: 95
GLUE Sortino Ratio Rank: 96
GLUE Omega Ratio Rank: 92
GLUE Calmar Ratio Rank: 95
GLUE Martin Ratio Rank: 94

NUTX

NUTX Risk / Return Rank: 30
NUTX Sharpe Ratio Rank: 29
NUTX Sortino Ratio Rank: 36
NUTX Omega Ratio Rank: 35
NUTX Calmar Ratio Rank: 24
NUTX Martin Ratio Rank: 27

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GLUE vs. NUTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Monte Rosa Therapeutics, Inc. (GLUE) and Nutex Health Inc (NUTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GLUE	NUTX	Difference
Sharpe ratio Return per unit of total volatility	3.20	-0.27	+3.47
Sortino ratio Return per unit of downside risk	4.33	0.24	+4.09
Omega ratio Gain probability vs. loss probability	1.50	1.03	+0.47
Calmar ratio Return relative to maximum drawdown	7.75	-0.47	+8.22
Martin ratio Return relative to average drawdown	17.17	-0.70	+17.87
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GLUE vs. NUTX - Sharpe Ratio Comparison

The current GLUE Sharpe Ratio is 3.20, which is higher than the NUTX Sharpe Ratio of -0.27. The chart below compares the historical Sharpe Ratios of GLUE and NUTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	GLUE	NUTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.20	-0.27	+3.47
Sharpe Ratio (All Time) Calculated using the full available price history	-0.03	-0.46	+0.42

Drawdowns

GLUE vs. NUTX - Drawdown Comparison

The maximum GLUE drawdown since its inception was -94.08%, smaller than the maximum NUTX drawdown of -99.93%. Use the drawdown chart below to compare losses from any high point for GLUE and NUTX.

Drawdown Indicators

	GLUE	NUTX	Difference
Max Drawdown Largest peak-to-trough decline	-94.08%	-99.93%	+5.85%
Max Drawdown (1Y) Largest decline over 1 year	-41.84%	-54.32%	+12.48%
Max Drawdown (3Y) Largest decline over 3 years	-67.19%	-94.36%	+27.17%
Current Drawdown Current decline from peak	-57.97%	-97.92%	+39.95%
Average Drawdown Average peak-to-trough decline	-74.62%	-97.27%	+22.65%
Ulcer Index Depth and duration of drawdowns from previous peaks	18.89%	36.42%	-17.53%

Volatility

GLUE vs. NUTX - Volatility Comparison

The current volatility for Monte Rosa Therapeutics, Inc. (GLUE) is 17.10%, while Nutex Health Inc (NUTX) has a volatility of 25.88%. This indicates that GLUE experiences smaller price fluctuations and is considered to be less risky than NUTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GLUE	NUTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.10%	25.88%	-8.78%
Volatility (6M) Calculated over the trailing 6-month period	57.34%	67.20%	-9.86%
Volatility (1Y) Calculated over the trailing 1-year period	92.88%	95.75%	-2.87%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	101.35%	133.36%	-32.01%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	101.35%	133.36%	-32.01%

Dividends

GLUE vs. NUTX - Dividend Comparison

Neither GLUE nor NUTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both GLUE and NUTX in my portfolio?

GLUE and NUTX have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GLUE or NUTX?

NUTX has higher volatility (25.88%) compared to GLUE (17.10%). In terms of maximum drawdown, GLUE dropped -94.08% vs NUTX's -99.93%.

Which has better risk-adjusted returns?

GLUE currently has the higher Sharpe Ratio (3.20 vs -0.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.